Early treatment

Neurological Sciences

Volumn 27, Issue SUPPL. 1, 2006, Pages

  Comi, Gian Carlo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Clinical trials; Immunomodulatory treatments; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AXONAL INJURY; BRAIN ATROPHY; CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PREDICTION; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 33646784641     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0538-6     Document Type: Article

References (42)

1. Weinshenker BG (1994) Natural history of multiple sclerosis. Ann Neurol 36[Suppl]:6-11
2. Optic Neuritis Study Group (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 121:944-949
3. Optic Neuritis Study Group (2004) Neurologic impairment 10 years after optic neuritis. Arch Neurol 61:1386-1389
4. Iannucci G, Tortorella C, Rovaris M et al (2000) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 21:1034-1038
5. O'Riordan JI, Thompson AJ, Kingsley PE et al (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495-503
6. Yu BM, Johnson MJ, Tuohy VK (1996) A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183:1777-1788
7. Goebels N, Hofstetter H, Schmidt S et al (2000) Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: Epitope spreading versus clonal persistence. Brain 123:508-518
8. Balashov KE, Smith DR, Khoury SJ et al (1997) Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94:599-603
9. Nicoletti F, Patti F, Cocuzza C et al (1996) Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 70:87-90
10. Lassmann H (1998) Neuropathology in multiple sclerosis: New concepts. Mult Scler 4:93-98
11. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274
12. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
13. Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
14. Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212
15. Matthews PM, De Stefano N, Narayanan S et al (1998) Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin Neurol 18:327-336
16. Falini A, Calabrese G, Filippi M et al (1998) Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability. AJNR Am J Neuroradiol 19:223-229
17. Rocca MA, Mastronardo G, Rodegher M et al (1999) Longterm changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 20:821-827
18. Losseff NA, Webb SL, O'Riordan JI et al (1996) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701-708
19. Rudick RA, Fisher E, Lee JC et al (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698-1704
20. van Waesberghe JH, Kampphorst W, De Groot CJ et al (1999) Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
21. Gass A, Barker GJ, Kidd D et al (1994) Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 36:62-67
22. Filippi M, Iannucci G, Tortorella C et al (1999) Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52:588-594
23. Pagani E, Filippi M, Rocca MA, Horsfield MA (2005) A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: Application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 26:258-265
24. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 10:1698-1704
25. Simon JH, Jacobs LD, Campion MK et al (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53:139-148
26. Filippi M, Rovaris M, Inglese M et al (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 364:1489-1496
27. Filippi M, Rocca MA, Mezzapesa DM et al (2004) Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Hum Brain Mapp 21:108-117
28. Beck RW, Cleary PA, Trobe JD et al (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764-1769
29. Comi G, Filippi M, Barkhof F and the ETOMS Study Group (2001) Effects of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
30. Jacobs LD, Beck RW, Simon JH and the CHAMPS Study Group (2000) Intramuscular interferon b-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
31. PRISMS (Prevention of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/ remitting multiple sclerosis. Lancet 352:1498-1504
32. Rudick RA, Fisher E, Lee JC et al (2000) Brain atrophy in relapsing-remitting multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 6:365-372
33. Sormani MP, Rovaris M, Valsasina P et al (2004) Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62:1432-1434
34. Kappos L, Polman C, Freedman MS et al on behalf of the BENEFIT Study Group (2005). Betaferon, in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Clinical results. Mult Scler 11[Suppl 1]:10
35. Jones CA, Riddehough A, Li DK et al (2003) MRI cerebral atrophy in relapsing remitting MS: Results from the PRISMS trial. Neurology 56[Suppl 3]:379
36. Molyneux PD, Kappos L, Polman C et al (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256-2263
37. Filippi M, Rovaris M, Iannucci G et al (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55:1714-1718
38. Paolillo A, Coles AJ, Molyneux PD et al (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53:721-757
39. Rudick RA, Fisher E, Lee JC et al (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple sclerosis collaborative research group. Neurology 53:1698-1704
40. Zivadinov R, Rudick RA, De Masi R (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239-1247
41. Sormani MP, Rovaris M, Valsasina P et al (2004) Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62:1432-1434
42. Filippi M, Rovaris M, Inglese M et al (2004). Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 364:1489-1496